Literature DB >> 28004347

Optimal Affinity of a Monoclonal Antibody: Guiding Principles Using Mechanistic Modeling.

Abhinav Tiwari1, Anson K Abraham2, John M Harrold3, Anup Zutshi4, Pratap Singh5.   

Abstract

Affinity optimization of monoclonal antibodies (mAbs) is essential for developing drug candidates with the highest likelihood of clinical success; however, a quantitative approach for setting affinity requirements is often lacking. In this study, we computationally analyzed the in vivo mAb-target binding kinetics to delineate general principles for defining optimal equilibrium dissociation constant ([Formula: see text]) of mAbs against soluble and membrane-bound targets. Our analysis shows that in general [Formula: see text] to achieve 90% coverage for a soluble target is one tenth of its baseline concentration ([Formula: see text]), and is independent of the dosing interval, target turnover rate or the presence of competing ligands. For membrane-bound internalizing targets, it is equal to the ratio of internalization rate of mAb-target complex and association rate constant ([Formula: see text]). In cases where soluble and membrane-bound forms of the target co-exist, [Formula: see text] lies within a range determined by the internalization rate ([Formula: see text]) of the mAb-membrane target complex and the ratio of baseline concentrations of soluble and membrane-bound forms ([Formula: see text]). Finally, to demonstrate practical application of these general rules, we collected target expression and turnover data to project [Formula: see text] for a number of marketed mAbs against soluble (TNFα, RANKL, and VEGF) and membrane-bound targets (CD20, EGFR, and HER2).

Entities:  

Keywords:  PK half-life; binding affinity; lead optimization; membrane-bound target; soluble target

Mesh:

Substances:

Year:  2016        PMID: 28004347     DOI: 10.1208/s12248-016-0004-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  34 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 2.  Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins.

Authors:  Iftekhar Mahmood; Martin D Green
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapies.

Authors:  Mark Penney; Balaji Agoram
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

4.  Semimechanistic model to characterize nonlinear pharmacokinetics of nimotuzumab in patients with advanced breast cancer.

Authors:  Leyanis Rodríguez-Vera; Mayra Ramos-Suzarte; Eduardo Fernández-Sánchez; Jorge Luis Soriano; Concepción Peraire Guitart; Gilberto Castañeda Hernández; Carlos O Jacobo-Cabral; Niurys de Castro Suárez; Helena Colom Codina
Journal:  J Clin Pharmacol       Date:  2015-04-24       Impact factor: 3.126

5.  Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use.

Authors:  C Emmons; L G Hunsicker
Journal:  Iowa Med       Date:  1987-02

6.  Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.

Authors:  X D Yang; X C Jia; J R Corvalan; P Wang; C G Davis; A Jakobovits
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

7.  Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  MAbs       Date:  2013-02-13       Impact factor: 5.857

Review 8.  Target site occupancy: emerging generalizations from clinical and preclinical studies.

Authors:  Sarah Grimwood; Paul R Hartig
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

9.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

10.  Assessing the Impact of Tissue Target Concentration Data on Uncertainty in In Vivo Target Coverage Predictions.

Authors:  A Tiwari; H Luo; X Chen; P Singh; I Bhattacharya; P Jasper; J E Tolsma; H M Jones; A Zutshi; A K Abraham
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-10-22
View more
  7 in total

1.  Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Authors:  Sameed Ahmed; Miandra Ellis; Hongshan Li; Luca Pallucchini; Andrew M Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-29       Impact factor: 2.745

2.  Role of Interstitial Fluid Turnover on Target Suppression by Therapeutic Biologics Using a Minimal Physiologically Based Pharmacokinetic Model.

Authors:  Xiaobing Li; William J Jusko; Yanguang Cao
Journal:  J Pharmacol Exp Ther       Date:  2018-07-12       Impact factor: 4.030

3.  Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.

Authors:  Bing Wang; Chi-Yuan Wu; Denise Jin; Paolo Vicini; Lorin Roskos
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-11-23

4.  Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.

Authors:  Tomoki Yoneyama; Mi-Sook Kim; Konstantin Piatkov; Haiqing Wang; Andy Z X Zhu
Journal:  PLoS Comput Biol       Date:  2022-07-15       Impact factor: 4.779

5.  Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR.

Authors:  Jan Fredrik Simons; Yoong Wearn Lim; Kyle P Carter; Ellen K Wagner; Nicholas Wayham; Adam S Adler; David S Johnson
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

Review 6.  Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.

Authors:  Yu Tang; Yanguang Cao
Journal:  Pharmaceutics       Date:  2021-03-21       Impact factor: 6.321

Review 7.  Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.

Authors:  Irina Kareva; Anup Zutshi; Cristina Vazquez Mateo; Orestis Papasouliotis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-30       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.